Remedica has signed a non-binding memorandum of understanding (MoU) with AJA Pharma, a subsidiary of Saudi Chemical Company Holding (SCCH), during CPHI Milan, marking the beginning of a strategic collaboration.

As part of this partnership, Remedica and AJA Pharma will join forces to develop medicines and transfer technology, combining the strengths of the two companies to drive innovation and enter new markets.

“The Saudi market is not only pivotal in the Middle East, but also increasingly influential on the global stage. Its rapid growth, strategic geographic position, and ambitious Vision 2030 reform plan make it a key player in shaping future economic trends and driving innovation across the healthcare industry. We are excited about our partnership with AJA Pharma that reinforces our shared mission to deliver innovative and high-quality pharmaceutical solutions and expands our reach to patient needs across key disease areas like Oncology, Cardiovascular, and Diabetes, in both tablets and injectables” – Vijay Zutshi, Chief Commercial & Strategy Officer at Remedica says.